Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lonza Expands HPAPI Capacity in Visp | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lonza Expands HPAPI Capacity in Visp

Will establish new commercial-scale capabilities for the manufacture of complex and highly potent active pharmaceutical ingredients and ADC payload-linkers.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Lonza

Editor’s take: Investment supports Lonza’s efforts to expand its position in the ADC space by further developing its integrated ADC offering and expanding commercial-scale supply of highly potent payload-linker molecules.

Lonza announced plans to enhance its drug-linker center of excellence and expand payload-linker manufacturing capacity at its Visp site. The expansion will establish new commercial-scale capabilities for the manufacture of highly complex and highly potent active pharmaceutical ingredients (HPAPI) and ADC payload-linkers.

The investment will add new manufacturing capacity within an existing GMP facility, bringing additional payload-linker production and purification alongside dedicated analytical and process development labs. The facility is designed for multipurpose use and scale-out, enabling flexible production of a broad range of payload-linker molecules, with the option to add additional suites as customer demand grows.

The new capacity is closely connected to Lonza’s broader integrated ADC ecosystem in Visp, which includes monoclonal antibody manufacture, conjugation and drug product (DP) manufacturing capabilities in Visp and Stein (CH) and additional quality control (QC) capacity capable of handling highly potent payload-linker molecules. The facility is expected to be operational in 2028.

Christian Seufert, Head of Advanced Synthesis, Lonza, said: “The rapid growth of the ADC market is driving increasing demand for highly complex payload-linkers that require advanced manufacturing capabilities. Lonza remains committed to investing and further developing its integrated ADC offering. This investment reflects that commitment by expanding our capacity to support this next generation of therapies and enabling our customers to progress efficiently from development to commercial supply.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics